Is BioStem Technologies, Inc. (BSEM) a Buy, Sell, or Hold?
OTC : BSEM
BioStem Technologies, Inc.
$4.093 USD
$0.07 (1.82%)
- Volume
- 253.89K
- Average Volume
- 55.33K
- Market Capitalization
- $69.52M
- P/E Ratio
- -3.47
- Dividend Yield
- 0.00%
- Price Target
- $9.00
- Year High
- $10.71
- Year Low
- $3.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.14
Company Overview
OTC
Jason Matuszewski
Biotechnology
Healthcare
BSEM
73
US
USD
Liquidity Metrics
0.10
1.14
0.95
0.59
0.00
Sales & Valuation
$47.48M
-3.68
2.16
37.52
0.11
Profitability
-$0.39
-$6.58M
105.15%
76.62%
-47.03%
-36.10%
P/E Metrics
-3.47
0.04
0.04
Analyst Price Target & Rating
$9.00
$9.00
$9.00
2/5
0 Analysts
-54.52%
Financial Health Scores
-0.13
3/9
$3.29M
$55.08M
$23.21M
-$14.82M
Key Metrics (TTM)
$59.09M
-3.12
-4.19
1.14
-47.03%
-42.17%
-28.83%
2.67%
-87 days
Company Executives
| Name | Title |
|---|---|
| Barry J. Hassett | Chief Commercial Officer |
| Noah Agron | Vice President of Corporate Finance & Strategy |
| Katherine Gorrell | Chief Legal & Compliance Officer |
| David Woynarowski | Chief Medical Officer |
| Andrew Vanvurst | Chief Operating Officer & Director |
| Brandon Poe | Chief Financial Officer |
| Jason Matuszewski | Chief Executive Officer, President, Secretary & Chairman |
| Jeff Humke | Vice President of Human Resources |
| Larry Jones | Chief Revenue Officer |
| Michael Fortunato | Chief Accounting Officer |
| Irmgard Huber | International Medical Advisor & Interim Chief Medical Officer |
Poll Results
No votes yet today — be the first to share your view!
About BioStem Technologies, Inc. (OTC:BSEM) Stock
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 201 ... 4. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
BioStem Technologies Announces Nasdaq Uplisting
2026-08-06 17:38:00
POMPANO BEACH, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that The Nasdaq Stock Market LLC (“Nasdaq”) has completed its review of the Company's listing application and approved the Company's common stock for listing on The Nasdaq Capital Market.
2026-07-29 16:05:00
POMPANO BEACH, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announces it will release its second quarter 2026 financial results on Wednesday, August 12, 2026, and will host a conference call and webcast at 4:30 PM ET.
2026-07-10 07:00:00
POMPANO BEACH, Fla., July 10, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced the filing of a Form 10 registration statement (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) to register its shares of common stock pursuant to the Securities Exchange Act of 1934, as amended, and reaffirmed its strategic decision to pursue a listing on the Nasdaq Stock Market (“Nasdaq”).
2026-07-08 08:00:00
Company Continues to Expand Intellectual Property Portfolio Supporting Advanced Placental Allograft Innovation POMPANO BEACH, FL / ACCESS Newswire / July 8, 2026 / BioStem Technologies, Inc. (OTCID:BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that the United States Patent and Trademark Office (USPTO) has issued four U.S. design patents covering the Company's proprietary fenestrated human placental allograft technologies. The newly issued patents strengthen BioStem's intellectual property portfolio and provide additional protection for innovative allograft designs in surgical and wound care applications.
BioStem Technologies to Present at the Planet MicroCap Las Vegas 2026 Conference
2026-06-10 16:05:00
POMPANO BEACH, Fla., June 10, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that Company management will present at the Planet MicroCap Las Vegas 2026 Conference.
BioStem Technologies Announces Appointment of Three New Members to its Board of Directors
2026-06-09 07:00:00
POMPANO BEACH, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced the appointment of Mark Glickman, Steven D.
2026-05-22 07:00:00
POMPANO BEACH, Fla., May 22, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc.(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with its first institutional investor for the purchase and sale of 746,269 shares of common stock at a price of $3.35 per share for aggregate gross proceeds of approximately $2.5 million.
BioStem Technologies Q1 Earnings Call Highlights
2026-05-15 23:06:41
BioStem Technologies OTCMKTS: BSEM said its first quarter of 2026 marked a major shift in its business model following a late-January acquisition that moved the company's focus from physician offices toward the hospital market.
Frequently Asked Questions
-
What is the current BioStem Technologies, Inc. (BSEM) stock price?
-
BioStem Technologies, Inc.(OTC:BSEM) stock price is $4.093 in the last trading session. During the trading session, BSEM stock reached the peak price of $10.71 while $3.01 was the lowest point it dropped to. The percentage change in BSEM stock occurred in the recent session was 1.82% while the dollar amount for the price change in BSEM stock was $0.07.
-
BSEM's industry and sector of operation?
-
The OTC listed BSEM is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BSEM?
-
Barry J. Hassett | Chief Commercial Officer
Noah Agron | Vice President of Corporate Finance & Strategy
Katherine Gorrell | Chief Legal & Compliance Officer
David Woynarowski | Chief Medical Officer
Andrew Vanvurst | Chief Operating Officer & Director -
How many employees does BSEM have?
-
Number of BSEM employees currently stands at 73. BSEM operates from 4901 Northwest 17th Way, Fort Lauderdale, FL 33309, US.
-
Link for BSEM official website?
-
Official Website of BSEM is: https://biostemtechnologies.com
-
How do I contact BSEM?
-
BSEM could be contacted at phone #954 380 8342 and can also be accessed through its website. BSEM operates from 4901 Northwest 17th Way, Fort Lauderdale, FL 33309, US.
-
How many shares of BSEM are traded daily?
-
The average number of BSEM shares traded daily for last 3 months was 55.33K.
-
What is the market cap of BSEM currently?
-
The market value of BSEM currently stands at $69.52M with its latest stock price at $4.093